

Supprelin® LA (histrelin acetate subcutaneous implant)

When requesting Supprelin® LA (histrelin acetate subcutaneous implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines.

FDA-approved Indication

Supprelin® LA (histrelin acetate subcutaneous implant) is indicated for the treatment of children with central precocious puberty.

Coverage Guidelines

The individual has a diagnosis of central precocious puberty.

Approval duration: 12 months

Recommended Dosing

The recommended dose is 50 mg implant inserted subcutaneously in the upper arm once every 12 months.

References

1. Supprelin® LA [prescribing information]. Malvern, PA; Endo Pharmaceuticals Solutions Inc., April 2022.
2. Eugster EA. Treatment of central precocious puberty. *J Endo Soc.* 2019;3:965-972.
3. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics.* 2009 Apr;123(4):e752-62.
4. Krishna KB, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. *Horm Res Paediatr.* 2019;91:357-372.